AnGes Past Earnings Performance
Past criteria checks 0/6
AnGes's earnings have been declining at an average annual rate of -27.7%, while the Biotechs industry saw earnings growing at 23% annually. Revenues have been declining at an average rate of 51.7% per year.
Key information
-27.7%
Earnings growth rate
-16.8%
EPS growth rate
| Biotechs Industry Growth | 31.9% |
| Revenue growth rate | -51.7% |
| Return on equity | -28.5% |
| Net Margin | -4,892.8% |
| Next Earnings Update | 10 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How AnGes makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 152 | -7,437 | 2,511 | 6,172 |
| 30 Sep 23 | 124 | -9,318 | 2,585 | 7,311 |
| 30 Jun 23 | 87 | -12,119 | 2,382 | 7,546 |
| 31 Mar 23 | 68 | -14,687 | 2,277 | 10,311 |
| 31 Dec 22 | 67 | -14,714 | 2,104 | 10,999 |
| 30 Sep 22 | 65 | -11,917 | 2,411 | 10,820 |
| 30 Jun 22 | 72 | -13,650 | 2,102 | 12,439 |
| 31 Mar 22 | 68 | -13,299 | 2,248 | 10,634 |
| 31 Dec 21 | 64 | -13,675 | 2,189 | 10,783 |
| 30 Sep 21 | 55 | -12,987 | 4,259 | 10,406 |
| 30 Jun 21 | 46 | -9,763 | 3,491 | 7,653 |
| 31 Mar 21 | 45 | -6,604 | 2,439 | 5,584 |
| 31 Dec 20 | 39 | -4,209 | 1,571 | 3,796 |
| 30 Sep 20 | 31 | -4,154 | 1,164 | 2,508 |
| 30 Jun 20 | 170 | -3,673 | 1,185 | 2,189 |
| 31 Mar 20 | 255 | -3,485 | 1,268 | 2,843 |
| 31 Dec 19 | 326 | -3,750 | 1,184 | 2,215 |
| 30 Sep 19 | 656 | -3,564 | 1,160 | 2,879 |
| 30 Jun 19 | 605 | -3,822 | 1,059 | 3,268 |
| 31 Mar 19 | 612 | -3,643 | 922 | 2,539 |
| 31 Dec 18 | 610 | -2,996 | 883 | 2,539 |
| 30 Sep 18 | 387 | -2,607 | 902 | 1,665 |
| 30 Jun 18 | 373 | -2,612 | 955 | 1,610 |
| 31 Mar 18 | 356 | -2,790 | 883 | 1,725 |
| 31 Dec 17 | 365 | -3,764 | 861 | 2,600 |
| 30 Sep 17 | 513 | -4,312 | 797 | 3,178 |
| 30 Jun 17 | 514 | -4,250 | 727 | 3,170 |
| 31 Mar 17 | 514 | -5,057 | 770 | 4,072 |
| 31 Dec 16 | 514 | -4,776 | 800 | 4,188 |
| 30 Sep 16 | 366 | -4,959 | 944 | 4,140 |
| 30 Jun 16 | 359 | -4,928 | 905 | 4,231 |
| 31 Mar 16 | 432 | -4,490 | 869 | 3,763 |
| 31 Dec 15 | 430 | -4,143 | 882 | 3,532 |
| 30 Sep 15 | 948 | -3,286 | 808 | 3,213 |
| 30 Jun 15 | 975 | -3,441 | 809 | 3,232 |
| 31 Mar 15 | 908 | -2,814 | 762 | 2,738 |
| 31 Dec 14 | 909 | -2,369 | 687 | 2,338 |
| 30 Sep 14 | 381 | -2,528 | 673 | 2,013 |
| 30 Jun 14 | 351 | -1,725 | 645 | 1,315 |
| 31 Mar 14 | 448 | -1,481 | 657 | 1,156 |
| 31 Dec 13 | 491 | -1,409 | 688 | 1,024 |
| 30 Sep 13 | 473 | -1,433 | 730 | 959 |
| 30 Jun 13 | 470 | -1,467 | 799 | 990 |
Quality Earnings: 4563 is currently unprofitable.
Growing Profit Margin: 4563 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4563 is unprofitable, and losses have increased over the past 5 years at a rate of 27.7% per year.
Accelerating Growth: Unable to compare 4563's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4563 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.9%).
Return on Equity
High ROE: 4563 has a negative Return on Equity (-28.49%), as it is currently unprofitable.